Abstract
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Current Drug Targets
Title: Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists
Volume: 1 Issue: 3
Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan and D. P. Mikhailidis
Affiliation:
Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide
Abstract: Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.
Export Options
About this article
Cite this article as:
Khan A. M., Calvert C. R., Sullivan E. M., Thomson S. C., Mumtaz H. F., Morgan J. R. and Mikhailidis P. D., Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349164
DOI https://dx.doi.org/10.2174/1389450003349164 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HM74a Agonists: Will they be the New Generation of Nicotinic Acid?
Current Topics in Medicinal Chemistry Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry β-Lactam Cholesterol Absorption Inhibitors
Current Medicinal Chemistry Subject Index to Volume 2
Current Vascular Pharmacology Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches
Current Medicinal Chemistry Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity
Current Chemical Biology Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry